FDA advisory panel backs Chelsea Therapeutics drug<p><a href="http://news.yahoo.com/u-advisory-panel-backs-approval-chelsea-drug-northera-220112030--finance.html"><img src="http://l2.yimg.com/bt/api/res/1.2/UJ.P1bBhSUWpeu4cW3E8gg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-01-14T232630Z_1_CBREA0D1T4900_RTROPTP_2_HEALTH.JPG" width="130" height="86" alt="The headquarters of the U.S. Food and Drug Administration is shown in Silver Spring near Washington" align="left" title="The headquarters of the U.S. Food and Drug Administration is shown in Silver Spring near Washington" border="0" /></a>By Toni Clarke WASHINGTON (Reuters) - A drug to treat a rare form of low blood pressure made by Chelsea Therapeutics International Ltd is effective enough to warrant regulatory approval, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. The panel voted 16 to 1 in favor of the drug, Northera, for patients with neurogenic orthostatic hypotension (NOH), a rare, chronic type of low blood pressure that occurs on standing and is associated with certain neurological disorders such as Parkinson's disease. Chelsea shares more than doubled in after-hours trading. The FDA is not bound to follow the advice of its panels but typically does so.</p><br clear="all"/>
Source: FDA advisory panel backs Chelsea Therapeutics drug (http://news.yahoo.com/u-advisory-panel-backs-approval-chelsea-drug-northera-220112030--finance.html)